NCT06924749View on ClinicalTrials.gov

Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia

PHASE2CompletedINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

June 2, 2024

Study Completion Date

July 2, 2024

Conditions

Pneumonia, InterstitialCancer Patients

Interventions

DRUG

EGCG

"EGCG (high pressure liquid chromatographic purity~≥ 95%; from Ningbo Hepu Biotechnology Co., Ltd.) is dissolved in 0.9% normal saline; 10ml is inhaled by atomization three times a day."

Trial Locations (2)

250117

Shan Dong cancer hospital and institute, Jinan

Shandong Cancer Hospital

Hanxi Zhao, Jinan

All Listed Sponsors

lead

Shandong Cancer Hospital and Institute

OTHER

NCT06924749 - Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia | Biotech Hunter | Biotech Hunter